导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.20% | 1536/4783 |
| 近一周 | -8.00% | 3985/5283 |
| 近一月 | -6.46% | 3669/5237 |
| 近一季 | -2.36% | 2650/5027 |
| 近半年 | -3.11% | 2698/4807 |
| 近一年 | 25.89% | 1484/4070 |
| 近两年 | 51.31% | 1209/2862 |
| 近三年 | 24.98% | 1163/2177 |
| 成立以来 | 70.59% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.86% 1154/4961 |
17.90% 1443/5312 |
- - |
- - |
| 2025 | 25.68% 1693/4813 |
1.58% 1589/3635 |
2.50% 1535/4076 |
20.84% 1910/4524 |
-0.11% 2361/4813 |
| 2024 | 5.32% 1841/3463 |
-2.12% 1320/2808 |
-4.41% 1503/3014 |
13.76% 2114/3129 |
-1.05% 1571/3463 |
| 2023 | -7.59% 929/2656 |
7.44% 574/2280 |
-3.85% 929/2385 |
-4.66% 1194/2515 |
-6.17% 1652/2655 |
| 2022 | -17.52% 602/2207 |
-12.19% 583/1919 |
2.74% 1264/2016 |
-10.44% 404/2113 |
2.09% 1043/2208 |
| 2021 | 15.47% 306/1822 |
0.35% 300/1255 |
8.04% 650/1330 |
5.55% 268/1466 |
0.91% 1046/1822 |
| 2020 | 30.55% 520/1250 |
-1.63% 226/1028 |
14.97% 529/1067 |
9.92% 605/1164 |
5.02% 814/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中泰中证500指数增强C VS. 长安沪深300非周期A(740101) |